Inhalon Biopharma

Inhalon Biopharma

Biotechnology, 1 Corporate Woods Dr, Durham, North Carolina, 63044, United States, 1-10 Employees

inhalon.com

  • LinkedIn

phone no Phone Number: 16*********

Who is INHALON BIOPHARMA

Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainf...

Read More

map
  • 1 Corporate Woods Dr, Durham, North Carolina, 63044, United States Headquarters: 1 Corporate Woods Dr, Durham, North Carolina, 63044, United States
  • 2018 Date Founded: 2018
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from INHALON BIOPHARMA

Inhalon Biopharma Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Inhalon Biopharma

Answer: Inhalon Biopharma's headquarters are located at 1 Corporate Woods Dr, Durham, North Carolina, 63044, United States

Answer: Inhalon Biopharma's phone number is 16*********

Answer: Inhalon Biopharma's official website is https://inhalon.com

Answer: Inhalon Biopharma's revenue is Under $1 Million

Answer: Inhalon Biopharma's SIC: 2836

Answer: Inhalon Biopharma's NAICS: 325414

Answer: Inhalon Biopharma has 1-10 employees

Answer: Inhalon Biopharma is in Biotechnology

Answer: Inhalon Biopharma contact info: Phone number: 16********* Website: https://inhalon.com

Answer: Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications and sometimes death. Our breakthrough discovery enables inhaled antibodies to trap pathogens (i.e. viruses, bacteria, fungi) in the lung mucus, which in turn block the infections from further spreading locally and facilitate the rapid elimination of the pathogens from the lung through normal mucus clearance. Although mucus in the lung airways is designed to protect the body from infections, pathogens have evolved to move easily through mucus to infect cells in the airways. Inhalon was launched based on the discovery of a new immune function antibodies trapping pathogens in mucus and molecular and biophysical insights into how to tune the antibody-mucin affinity. These muco-trapping antibodies bind to pathogens and crosslink them to mucins. Trapped pathogens are unable to infect cells and are rapidly eliminated by normal mucus clearance every 30 to 60 minutes swept into the digestive tract and become sterilized by gastric acid. This muco-trapping function is mediated by glycans in the antibodys Fc region and enhanced through the normal glycosylation process using Inhalon engineered production cell lines. This muco-trapping phenomenon has been confirmed with over a half dozen pathogens to date.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access